Key points from article :
Lento Bio, Inc. is focused on developing small-molecule therapeutics to target molecular damage driving age-related disease.
The company will initially focus on developing pharmaceutical eyedrops to treat a common vision disorder, presbyopia, or age-related farsightedness.
Presbyopia is caused by stiffening of the eye lens, which stems from molecular crosslinks including advanced glycation end products (AGE).
The small molecule drugs being developed will reverse the process of tissue-stiffening in the ocular lens.
It plans to apply its anti-glycation products more widely to include systemic diseases of aging.
“We see tremendous potential in Lento Bio’s approach to target myriad systemic diseases,” says Dr. Kelsey Moody,, CEO, Ichor Life Sciences.
“Lento Bio ... accelerate the creation of clinical assets and validate our disease hypothesis,” says Dr. Kris Barnes, CEO, Lento Bio.
Lento Bio will be supported and incubated by Ichor Life Sciences at Clarkson University’s Peyton Hall Biotechnology Incubator.
